Home  »  Company   »  After The Stock Rose 1.25% Over The Week, Is Brist...

After The Stock Rose 1.25% Over The Week, Is Bristol-Myers Squibb Company (NYSE: BMY) Still A Buy?

Bristol-Myers Squibb Company (NYSE:BMY)’s traded shares stood at 21.49 million during the last session, with the company’s beta value hitting 0.44. At the close of trading, the stock’s price was $66.53, to imply a decrease of -0.85% or -$0.57 in intraday trading. The BMY share’s 52-week high remains $81.43, putting it -22.4% down since that peak but still an impressive 1.88% since price per share fell to its 52-week low of $65.28. The company has a valuation of $141.33B, with an average of 8.57 million shares in intraday trading volume over the past 10 days and average of 8.02 million shares over the past 3 months.

Analysts have given a consensus recommendation of an Overweight for Bristol-Myers Squibb Company (BMY), translating to a mean rating of 2.40. Of 21 analyst(s) looking at the stock, 1 analyst(s) give BMY a Sell rating. 1 of those analysts rate the stock as Overweight while 10 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $1.99.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Bristol-Myers Squibb Company (NYSE:BMY) trade information

After registering a -0.85% downside in the last session, Bristol-Myers Squibb Company (BMY) has traded red over the past five days. The stock hit a weekly high of 67.72 this Friday, 03/17/23, dropping -0.85% in its intraday price action. The 5-day price performance for the stock is 1.25%, and -6.91% over 30 days. With these gigs, the year-to-date price performance is -7.53%. Short interest in Bristol-Myers Squibb Company (NYSE:BMY) saw shorts transact 20.96 million shares and set a 2.29 days time to cover.

Analysts on Wall Street suggest a consensus price target of $80.44, implying an increase of 17.29% to the stock’s current value. The extremes give us $62.00 and $95.00 for target low and target high price respectively. As such, BMY has been trading -42.79% off suggested target high and 6.81% from its likely low.

Bristol-Myers Squibb Company (BMY) estimates and forecasts

Looking at statistics comparing Bristol-Myers Squibb Company share performance against respective industry, we note that the company has underperformed competitors. Bristol-Myers Squibb Company (BMY) shares are -7.31% down over the last 6 months, with its year-to-date growth rate lower than industry average at 4.68% against 9.60%. Revenue is forecast to grow 1.50% this quarter before jumping 9.30% for the next one. The rating firms project that company’s revenue will grow 1.80% compared to the previous financial year.

Revenue forecast for the current quarter as set by 10 analysts is $11.52 billion. Meanwhile, for the quarter ending Jun 2023, a total of 10 analyst(s) estimate revenue growth to $11.97 billion.Earnings reports from the last fiscal year show that sales brought in $11.65 billion and $11.89 billion respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -1.10% before jumping 0.70% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 4.50% for the past 5-year period. While 2023 is set for a -5.40% return in earnings, projections for the next 5 years are at 4.06% annually.

BMY Dividends

Bristol-Myers Squibb Company has its next earnings report out on April 27. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Bristol-Myers Squibb Company has a forward dividend ratio of 2.28, with the share yield ticking at 3.43% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Bristol-Myers Squibb Company (NYSE:BMY)’s Major holders

Bristol-Myers Squibb Company insiders hold 0.07% of total outstanding shares, with institutional holders owning 79.40% of the shares at 79.45% float percentage. In total, 79.40% institutions holds shares in the company, led by Vanguard Group, Inc. (The). As of Sep 29, 2022, the company held over 199.89 million shares (or 9.40% of shares), all amounting to roughly $14.21 billion.

The next major institution holding the largest number of shares is Blackrock Inc. with 174.0 million shares, or about 8.18% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $12.37 billion.

We also have Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Bristol-Myers Squibb Company (BMY) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 63.7 million shares. This is just over 3.00% of the total shares, with a market valuation of $4.53 billion. Data from the same date shows that the other fund manager holds a little less at 48.4 million, or 2.28% of the shares, all valued at about 3.44 billion.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts